These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9169752)

  • 21. The importance of secreted virulence factors in Actinobacillus pleuropneumoniae bacterin preparation: a comparison.
    Fedorka-Cray PJ; Stine DL; Greenwald JM; Gray JT; Huether MJ; Anderson GA
    Vet Microbiol; 1993 Oct; 37(1-2):85-100. PubMed ID: 8296454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attenuated Actinobacillus pleuropneumoniae double-deletion mutant S-8∆clpP/apxIIC confers protection against homologous or heterologous strain challenge.
    Xie F; Li G; Zhou L; Zhang Y; Cui N; Liu S; Wang C
    BMC Vet Res; 2017 Jan; 13(1):14. PubMed ID: 28061786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Humoral antibody response and protective immunity in swine following immunization with the 104-kilodalton hemolysin of Actinobacillus pleuropneumoniae.
    Devenish J; Rosendal S; Bossé JT
    Infect Immun; 1990 Dec; 58(12):3829-32. PubMed ID: 2254012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nasal immunization with major epitope-containing ApxIIA toxin fragment induces protective immunity against challenge infection with Actinobacillus pleuropneumoniae in a murine model.
    Seo KW; Kim SH; Park J; Son Y; Yoo HS; Lee KY; Jang YS
    Vet Immunol Immunopathol; 2013 Jan; 151(1-2):102-12. PubMed ID: 23200821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of a non-hemolytic mutant of Actinobacillus pleuropneumoniae serotype 5: role of the 110 kilodalton hemolysin in virulence and immunoprotection.
    Inzana TJ; Todd J; Ma JN; Veit H
    Microb Pathog; 1991 Apr; 10(4):281-96. PubMed ID: 1895928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective efficacy of cell-free-antigen of Actinobacillus pleuropneumoniae in mice.
    Oishi E; Kitajima T; Ohgitani T; Katayama S; Okabe T
    J Vet Med Sci; 1995 Aug; 57(4):727-31. PubMed ID: 8519906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of immunogenicity and protective efficacy of Actinobacillus pleuropneumoniae HB04C(-) mutant lacking a drug resistance marker in the pigs.
    Bei W; He Q; Zhou R; Yan L; Huang H; Chen H
    Vet Microbiol; 2007 Nov; 125(1-2):120-7. PubMed ID: 17580102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel experimental model for the study and evaluation of experimental vaccines to Actinobacillus pleuropneumoniae.
    Montaraz JA; Rosales ME; Bautista E; Barcenas G; Lara V
    Vet Immunol Immunopathol; 1994 Jun; 41(3-4):375-80. PubMed ID: 7941315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA vaccine encoding type IV pilin of Actinobacillus pleuropneumoniae induces strong immune response but confers limited protective efficacy against serotype 2 challenge.
    Lu YC; Li MC; Chen YM; Chu CY; Lin SF; Yang WJ
    Vaccine; 2011 Oct; 29(44):7740-6. PubMed ID: 21835218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selection of serotype-specific vaccine candidate genes in Actinobacillus pleuropneumoniae and heterologous immunization with Propionibacterium acnes.
    Lei L; Sun C; Lu S; Feng X; Wang J; Han W
    Vaccine; 2008 Nov; 26(49):6274-80. PubMed ID: 18835316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction and characterization of a live, attenuated apxIICA inactivation mutant of Actinobacillus pleuropneumoniae lacking a drug resistance marker.
    Bei W; He Q; Yan L; Fang L; Tan Y; Xiao S; Zhou R; Jin M; Guo A; Lv J; Huang H; Chen H
    FEMS Microbiol Lett; 2005 Feb; 243(1):21-7. PubMed ID: 15667996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective efficacy of an affinity-purified hemolysin vaccine against experimental swine pleuropneumonia.
    Haga Y; Ogino S; Ohashi S; Ajito T; Hashimoto K; Sawada T
    J Vet Med Sci; 1997 Feb; 59(2):115-20. PubMed ID: 9070983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cross-protection experiments in pigs vaccinated with Actinobacillus pleuropneumoniae subtypes 1A and 1B.
    Jolie RA; Mulks MH; Thacker BJ
    Vet Microbiol; 1995 Aug; 45(4):383-91. PubMed ID: 7483251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of proteins of Propionibacterium acnes for use as vaccine candidates to prevent infection by the pig pathogen Actinobacillus pleuropneumoniae.
    Li L; Sun C; Yang F; Yang S; Feng X; Gu J; Han W; Langford PR; Lei L
    Vaccine; 2013 Oct; 31(45):5269-75. PubMed ID: 24051157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential growth characteristics and immunogenicity of tight and coasting temperature-sensitive mutants of Pseudomonas aeruginosa.
    Morris Hooke A; Sordelli DO; Cerquetti MC; Bellanti JA
    Infect Immun; 1987 Jan; 55(1):99-103. PubMed ID: 3098688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blood lymphocyte subsets in pigs vaccinated and challenged with Actinobacillus pleuropneumoniae.
    Appleyard GD; Furesz SE; Wilkie BN
    Vet Immunol Immunopathol; 2002 Jul; 86(3-4):221-8. PubMed ID: 12007888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Construction and immunogencity of a DeltaapxIC/DeltaapxIIC double mutant of Actinobacillus pleuropneumoniae serovar 1.
    Lin L; Bei W; Sha Y; Liu J; Guo Y; Liu W; Tu S; He Q; Chen H
    FEMS Microbiol Lett; 2007 Sep; 274(1):55-62. PubMed ID: 17608699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Construction and immunogenicity of an attenuated mutant of Actinobacillus pleuropneumoniae by insertional inactivation of apxIC].
    Xu FZ; Shi AH; Chen XL; Yang B; Wang JL
    Wei Sheng Wu Xue Bao; 2007 Oct; 47(5):923-7. PubMed ID: 18062275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the protective efficacy of Actinobacillus pleuropneumoniae serotype 1 detoxified lipopolysaccharides or O-polysaccharide-protein conjugate in pigs.
    Rioux S; Girard C; Dubreuil JD; Jacques M
    Res Vet Sci; 1998; 65(2):165-7. PubMed ID: 9839897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective efficacy of conjugate vaccines against experimental challenge with porcine Actinobacillus pleuropneumoniae.
    Byrd W; Harmon BG; Kadis S
    Vet Immunol Immunopathol; 1992 Nov; 34(3-4):307-24. PubMed ID: 1455686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.